People: Apricus Biosciences Inc (APRI.PH)

APRI.PH on Philadelphia Stock Exchange

3.37USD
22 May 2013
Price Change (% chg)

$-0.11 (-3.16%)
Prev Close
$3.48
Open
$3.36
Day's High
$3.37
Day's Low
$3.34
Volume
700
Avg. Vol
--
52-wk High
--
52-wk Low
--

Search Stocks

Summary

Name Age Since Current Position

Rusty Ray

 41 2012 Chairman of the Board

Richard Pascoe

 2013 Chief Executive Officer, Director

Steven Martin

 2013 Chief Financial Officer, Senior Vice President

Randy Berholtz

 50 2011 Executive Vice President, General Counsel, Secretary

Edward Cox

 31 2009 Vice President - Corporate Development and Investor Relations

Paul Maier

 65 2012 Director

Deirdre Gillespie

 56 2010 Independent Director

Leonard Oppenheim

 65 2007 Independent Director

Kleanthis Xanthopoulos

 54 2011 Independent Director
» Insider Trading

Biographies

Name Description

Rusty Ray

 Mr. Rusty Ray is Chairman of the Board of Apricus Biosciences Inc., since April 2012. He has been a director since December 2009. He is currently a partner with Brocair Partners, a healthcare-focused investment bank, and has been with Brocair Partners since its founding in 2004. Since joining Brocair, he has worked with a wide variety of clients across the healthcare industry ranging from pharmaceutical companies to early-stage drug development companies to medical device and service-based companies. Prior to joining Brocair Partners, Mr. Ray served as Deputy Director for eight years with Resources for the Future (“RFF”) a non-partisan Washington-based think tank that conducts independent economic research. During his tenure at RFF, the organization conducted a number of studies related to the pharmaceutical and biotechnology industries. Beyond life sciences, Mr. Ray also worked on issues related to emissions credit trading and utility restructuring. Prior to joining RFF, Mr. Ray worked with The Meningitis Research Foundation in London where he worked to support basic research to cure the disease. Ray holds an M.B.A. degree in Finance from the Fordham University School of Business, and received a B.S. degree in Biology from Wake Forest University.

Richard Pascoe

 Mr. Richard W. Pascoe has been appointed as Chief Executive Officer, Director of Apricus Biosciences, Inc., effective March 18, 2013. Prior to joining the Company, Mr. Pascoe was President and Chief Executive officer of Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company, from August 2008 through March, 2013. Prior to Somaxon, he was the Chief Operating Officer at ARIAD Pharmaceuticals, an emerging oncology company, where he led commercial operations, manufacturing, information services, program and alliance management and business development. Mr. Pascoe held a series of senior management roles at King Pharmaceuticals, Inc., including senior vice president of neuroscience marketing and sales and vice president positions in both international sales and marketing and hospital sales. He also held positions in the commercial groups at Medco Research, Inc. (which was acquired by King), COR Therapeutics, Inc., B. Braun Interventional and the BOC Group. Mr. Pascoe served as a commissioned officer in the United States Army following his graduation from the United States Military Academy at West Point where he received a B.S degree in Leadership.

Steven Martin

 Mr. Steven Martin is Chief Financial Officer, Senior Vice President of Apricus Biosciences, Inc. He has been appointed as Interim Chief Executive Officer of the company effective November 06, 2012. Mr. Martin has over 25 years of financial leadership experience with in growing public companies in a variety of industries, including life sciences. Since 2008, Mr. Martin served as Senior Vice President and Chief Financial Officer of BakBone Software, a publicly-traded software company. Mr. Martin also served as Interim CEO over the final 10 months with BakBone and through the sale of the company that was completed in January of 2011. From 2005 to 2007, Mr. Martin served as Chief Financial Officer of Stratagene Corporation, a publicly-traded company specializing in the development, manufacture and marketing of specialized research and clinical diagnostic products. Mr. Martin's experience also includes the position of Controller with publicly-traded Gen-Probe Incorporated, a life sciences company, as well as 10 years with the public accounting firm of Deloitte & Touche. Mr. Martin holds a Bachelors of Science degree from San Diego State University.

Randy Berholtz

 Mr. Randy Berholtz, Esq., is Executive Vice President, General Counsel, Secretary of Apricus Biosciences Inc., effective April 2011. From 2004 to 2010, he was the Vice President, General Counsel and Secretary of ACON Laboratories, Inc., a diagnostics company based in San Diego and Hangzhou, China. He was the Chief Operating Officer and General Counsel of Inglewood Ventures, LP, a life sciences venture capital firm, from 2003 to 2004. Mr. Berholtz was the Acting General Counsel and Secretary and earlier the Senior Corporate Counsel of Nanogen, Inc., a Nasdaq-listed genomics company from 2000 to 2003. He was an attorney with the law firms of Heller Ehrman, LLP and Cooley Godward, LLP in San Diego, with Cravath, Swaine & Moore in New York City and Kirkpatrick & Lockhart (now K&L Gates) in Pittsburgh, Pennsylvania. Mr. Berholtz holds a bachelor's degree (summa cum laude) from Cornell University, a master's degree from Oxford University where he was a Rhodes Scholar and a law degree from the Yale Law School.

Edward Cox

 Mr. Edward Cox is Vice President - Corporate Development and Investor Relations of Apricus Biosciences Inc., since December 2009. Mr. Cox was the President, director and Secretary of Bio-Quant, Inc. from January 2007 until the merger with Apricus Bio. Prior to that, he acted as a Business Strategist and Consultant for both public and private companies in the areas of Healthcare, Life Science, Technology and Resources. Mr. Cox holds a Master of Science degree in Business from the University of Florida.

Paul Maier

 Mr. Paul V. Maier has been appointed as Director of Apricus Biosciences, Inc., with effect from June 1, 2012. He is also Chief Financial Officer of Sequenom, Inc. Prior to joining Sequenom, Mr. Maier served as Senior Vice President and Chief Financial Officer of Ligand Pharmaceuticals, Inc. from 1992 until 2007, where he helped build Ligand from a venture stage company to a commercial, integrated biopharmaceutical organization. Prior to joining Ligand, he spent six years in various management and finance positions at ICN Pharmaceuticals. Mr. Maier received his M.B.A. from Harvard Business School and a B.S. from Pennsylvania State University.

Deirdre Gillespie

 Dr. Deirdre Y. Gillespie, M.D., is Independent Director of Apricus Biosciences Inc., since June 22, 2010. She is the former President and Chief Executive Officer of publicly-held La Jolla Pharmaceutical Company. She has over 20 years experience in general management in pharmaceutical and biotechnology companies. Prior to joining La Jolla Pharmaceutical Company, Dr. Gillespie served from 2001 to 2005 as President and Chief Executive Officer of Oxxon Therapeutics, Inc., a privately held pharmaceutical company spun out of Oxford University and ultimately acquired by Oxford Biomedica Plc. Before that, Dr. Gillespie was Chief Operating Officer of Vical, Inc., a publicly-traded gene delivery company, from 2000 to 2001, and Executive Vice President and Chief Business Officer of the company. During her career, Dr. Gillespie also held a number of senior strategic and commercial positions at DuPont Merck Pharmaceutical Company, from 1990 to 1996, including Vice President of Marketing, and at Sandoz Pharma AG (Novartis), in clinical development, from 1986 to 1990. Prior to that time, she spent five years in internal medicine in London and Oxford. Dr. Gillespie received her M.B.A. from the London Business School and her M.D. and B.Sc. from London University.

Leonard Oppenheim

 Mr. Leonard A. Oppenheim, Esq., is Independent Director of Apricus Biosciences Inc. He has been a director since 2004. Mr. Oppenheim served as the Chairman of the Board from June 2006 through June 2007. Mr. Oppenheim retired from business in 2001 and has since been active as a private investor. From 1999 to 2001, Mr. Oppenheim was a partner in Faxon Research, a company offering independent research to professional investors. From 1983 to 1999, Mr. Oppenheim was a principal in the Investment Banking and Institutional Sales division of Montgomery Securities. Prior to that, he was a practicing attorney. Mr. Oppenheim holds a J.D. degree from New York University Law School. He is currently a director of Sysorex Global Holdings Corp., a public company.

Kleanthis Xanthopoulos

 Dr. Kleanthis G. Xanthopoulos, Ph.D., is Independent Director of Apricus Biosciences, Inc., effective December 2011. Dr. Xanthopoulos has proven leadership and business and corporate development experience in the pharmaceutical industry. He is the President and Chief Executive Officer of Regulus Therapeutics Inc. (“Regulus”). Prior to joining Regulus in 2007, Dr. Xanthopoulos was the Managing Director of Enterprise Partners Venture Capital. He co-founded Anadys Pharmaceuticals, served as President and Chief Executive Officer from 2000 to 2006, and remained a Director until its acquisition by Roche in 2011. Before that, Dr. Xanthopoulos was Vice President at Aurora Biosciences (acquired by Vertex Pharmaceuticals) from 1997 to 2000, and Section Head of the National Human Genome Research Institute from 1995 to 1997. Previously, he was an Associate Professor at the Karolinska Institute, Stockholm, Sweden, after completing a Postdoctoral Research Fellow at The Rockefeller University, New York. An Onassis Foundation Scholar, Dr. Xanthopoulos received his B.Sc. in Biology with honors from Aristotle University of Thessaloniki, Greece, and his M.Sc. degree in Microbiology and Ph.D. degree in Molecular Biology from the University of Stockholm, Sweden. Dr. Xanthopoulos is a member of the board of directors of the Biotechnology Industry Organization (BIO), Sente Inc., and a member of the executive board of BIOCOM, Southern California's life science industry association.

Basic Compensation

Name Fiscal Year Total

Rusty Ray

 --

Richard Pascoe

 --

Steven Martin

 939,813

Randy Berholtz

 908,276

Edward Cox

 --

Paul Maier

 --

Deirdre Gillespie

 --

Leonard Oppenheim

 --

Kleanthis Xanthopoulos

 --
As Of 30 Dec 2011

Insider Trading

Name Shares Traded Price

XANTHOPOULOS KLEANTHIS G

 2,864 $2.63

XANTHOPOULOS KLEANTHIS G

 2,864 $2.50

XANTHOPOULOS KLEANTHIS G

 3,125 $3.25

DAMAJ BASSAM B

 249,002 $0.00

DAMAJ BASSAM B

 760 $2.77

DAMAJ BASSAM B

 1,500 $2.69

COX EDWARD M

 1,500 $2.73

RAY RUSTY

 4,000 $2.81

OPPENHEIM LEONARD A

 2,784 $5.13

RAY RUSTY

 2,784 $5.13

ESBER HENRY JEMIL

 2,505 $5.13

GILLESPIE DEIRDRE Y

 2,784 $5.13

XANTHOPOULOS KLEANTHIS G

 100,000 $0.00

RAY RUSTY

 2,784 $3.58

GILLESPIE DEIRDRE Y

 2,784 $3.58

ESBER HENRY JEMIL

 2,505 $3.58

OPPENHEIM LEONARD A

 2,784 $3.58

BERHOLTZ RANDY

 5,769 $0.00

OPPENHEIM LEONARD A

 2,784 $3.55

GILLESPIE DEIRDRE Y

 2,784 $3.55

ESBER HENRY JEMIL

 2,505 $3.55

RAY RUSTY

 2,784 $3.55

DAMAJ BASSAM B

 34,342 $0.00

DAMAJ BASSAM B

 90,167 $0.00

COX EDWARD M

 13,574 $0.00
» Full list on Insider Trading
Search Stocks